Evidence map›Paper›PMID 41776340›Full record

ReviewNPJ cardiovascular health2025

Cardiovascular complications of cellular immunotherapies and associated risk factors.

Eli Grunblatt, Nausheen Akhter

Abstract readReview
In one paragraph

Review in NPJ cardiovascular health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Eli GrunblattDepartment of Medicine, Feinberg School of Medicine, Northwestern University, 676 N. St. Clair, Suite 2330, Chicago, IL, 60611, USA.
Nausheen AkhterDivision of Cardiovascular Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, 676 N. St. Clair, Suite 600, Chicago, IL, 60611, USA. n-akhter@northwestern.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, the use of cellular immunotherapies has become widespread for the treatment of patients with refractory malignancies. While this has led to improved overall outcomes, these therapies have been associated with numerous, sometimes severe cardiotoxicities. In this review, we highlight the spectrum of cardiovascular adverse events that can occur following cellular immunotherapies with a particular emphasis on the pre-treatment risk factors that may be associated with these cardiotoxicities.

Identifiers

PMID41776340
PMCPMC12912347

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.